OSE Immunotherapeutics SA
PAR:OSE
OSE Immunotherapeutics SA
Non-Reccuring Items
OSE Immunotherapeutics SA
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Non-Reccuring Items
-€14k
|
CAGR 3-Years
64%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Non-Reccuring Items
-€490k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Non-Reccuring Items
€328k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
79%
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Non-Reccuring Items
-€8.4m
|
CAGR 3-Years
-844%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Non-Reccuring Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Non-Reccuring Items?
Non-Reccuring Items
-14k
EUR
Based on the financial report for Jun 30, 2025, OSE Immunotherapeutics SA's Non-Reccuring Items amounts to -14k EUR.
What is OSE Immunotherapeutics SA's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
64%
Over the last year, the Non-Reccuring Items growth was 46%. The average annual Non-Reccuring Items growth rates for OSE Immunotherapeutics SA have been 64% over the past three years .